We are pleased to announce that the first COVIDRIVE study has recruited 10,038 patients across 17 hospitals in 5 European countries. This high recruitment number is important […]
Author: COVIDRIVE consortium
Pfizer Inc. has joined COVIDRIVE
July, 01 2023 – Pfizer has joined the COVIDRIVE Consortium and officially become a COVIDRIVE partner. Pfizer will further contribute […]
AstraZeneca has published its first COVIDRIVE results in Lancet Regional Health Europe.
The study concluded that primary-series vaccination with AstraZeneca´s COVID-19 vaccine confers protection against COVID-19 hospitalisation with enduring levels of vaccine […]
Study investigator meeting in Copenhagen
On 16 April, 2023, during the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Copenhagen, Denmark, a hybrid […]
COVIDRIVE´s first German study site has been activated
The Study Contributor Universitätsklinikum Frankfurt was activated on 05 April 2023.
First face-to-face COVIDRIVE Steering Committee meeting
On November 14th and 15th, 2022, the city of Valencia became the epicentre of COVIDRIVE Partnership discussions. The members of the COVIDRIVE Steering Committee (SC) connected to share the vaccine company-specific COVID-19 vaccine effectiveness interim results, to review all progress made and to brainstorm about vaccination preparedness and sustainability of the COVIDRIVE consortium. The group met at the Hotel Las Arenas and went through a packed two-day agenda.
COVIDRIVE welcomes one new vaccine company to the consortium
13 July 2022 – Bavarian Nordic has joined the COVIDRIVE consortium and officially become
COVIDRIVE partner. Bavarian Nordic will further contribute to the assessment of the
effectiveness of COVID-19 vaccines in Europe to support the region’s public health response and
address the vaccine companies’ regulatory obligations.
COVIDRIVE welcomes three new vaccine companies to the consortium
Three new vaccine companies (Moderna, Novavax and Valneva) have joined the COVIDRIVE consortium and officially become COVIDRIVE partners. Moderna, Novavax and Valneva will further contribute to the assessment of the effectiveness of COVID-19 vaccines in Europe to support the region’s public health response and address the vaccine companies’ regulatory obligations.
Launch of an ambitious cross-pharma study by the public-private partnership ‘COVIDRIVE’: a multi-country European study to continuously monitor COVID-19 vaccine effectiveness against severe disease
17/09/2021- COVIDRIVE, a long-term, multi-country, hospital-based study investigating the effectiveness of COVID-19 vaccines across Europe has recently begun with the successful recruitment of its first patient – at a site in Valencia (Spain).
COVIDRIVE consists of a unique, cross-pharma consortium of vaccine companies and research groups who are joining forces to collect real-world data on the effectiveness of COVID-19 vaccines. This first COVIDRIVE study will monitor for variants of concern and help provide answers to the critical questions relating to COVID-19 vaccine effectiveness, including duration of protection of the different vaccines, impact of additional vaccine doses and different vaccine combinations.
New public-private partnership COVIDRIVE to assess brand-specific COVID-19 vaccine effectiveness in Europe
19/07/2021 – A new public-private partnership – COVIDRIVE – announced today that it will begin studies to assess the effectiveness of multiple COVID-19 vaccines in Europe to support the region’s public health response and to address the vaccine companies’ regulatory obligations. This multi-stakeholder partnership brings together public institutions, small medium enterprises and vaccine companies, including FISABIO (Spain), P95 (Belgium), THL (Finland), AstraZeneca (UK), CureVac (Germany), Janssen (Belgium), Sanofi-Pasteur (France) and GSK (Belgium).